Tunel aorto-ventricular izquierdo: una rara entidad en cardiología pediátrica

Andrés, Álvaro; Moreno, J.I. Carrasco; Martínez, F. Serrano

doi:10.1016/j.anpedi.2008.11.011

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the inclusion and exclusion criteria and propensity score matching process, there were only 45 patients in the intervention group. While the sample size is similar to many other SCIG studies,[82327282930] this limits its power to detect a rare AE and generalizability of the study results. This study did not include new-to-therapy patients; hence, we could not extrapolate our findings to new SCIG users.…”

Section: Discussionmentioning

confidence: 99%

Outcome evaluation of a subcutaneous immunoglobulin clinical management program

et al. 2019

View full text Add to dashboard Cite

Objective: The aim of this study is to compare clinical and cost outcomes of patients undergoing subcutaneous immunoglobulin (SCIG) therapy who were managed by a clinical management program to the matched controls in the United States. Methods: This was a retrospective cohort study using administrative claims data from the PharMetrics Plus™ (PMTX+) database. The patients from a high-touch SCIG clinical management program were matched to nonprogram patients in PMTX+ database using 1:4 propensity score matching without replacement. All patients were followed for 1 year during the study from September 1, 2011, to June 30, 2014, and both clinical and cost outcomes were compared between the two cohorts using the generalized estimating equation model. Findings: The clinical outcomes were measured by infection- and infusion-related adverse events (AEs). Most of them were not significantly different ( P > 0.05) between the intervention group and matched controls. Although the proportion of patients who had a mild less common AE was higher (4.4% vs. 0.0%;P = 0.04), it could be due to increased reporting among the intervention group. The annual adjusted mean total health-care costs of patients in the program ( n = 45) were $20,868 lower compared to matched controls ( n = 180), representing a 24% lower costs ($66,450 vs. $87,318;P = 0.009). Conclusion: This study may demonstrate that clinical management programs for SCIG may be associated with lower health-care costs and comparable infection and severe AE rates. The limitations of this study included a small sample size and a reliance on administrative claim data.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome evaluation of a subcutaneous immunoglobulin clinical management program

et al. 2019

View full text Add to dashboard Cite

show abstract

Espectro de las inmunodeficiencias primarias en un hospital de tercer nivel en un periodo de 10 años

Martin‐Nalda

Soler‐Palacín

Borén

et al. 2011

Anales de Pediatría

View full text Add to dashboard Cite

show abstract

Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy

Zhu¹,

Kirkham²,

Ayer³

et al. 2017

CEOR

View full text Add to dashboard Cite

ObjectiveTo compare clinical and economic outcomes of patients who received intravenous immunoglobulin (IVIG) therapies and were managed by a clinical management program vs the outcomes of matched controls using administrative claim data.MethodsThis retrospective cohort study used the PharMetrics Plus™ claim database between September 1, 2011 and June 30, 2014. Patients in the intervention group were from a “high-touch” IVIG clinical management program administered by a home infusion specialty pharmacy. A greedy propensity score matching algorithm was used to identify a control group from non-program patients. Generalized estimating equation models were employed to evaluate differences between cohorts who were followed for 1 year.ResultsClinical outcomes were measured as infections and infusion-related adverse events. The proportion of patients who had serious bacterial infections was significantly lower (4.13% vs 7.75%, P=0.049) in the intervention group (n=242) compared to the control group (n=968). Other clinical outcomes assessed were not different between cohorts (P>0.050). The economic outcomes were measured as healthcare costs. The annual adjusted mean total health care costs of patients in the program were $26,522 lower compared to matched controls, representing a 20% lower cost ($109,476 vs $135,998, P=0.002). A major contribution to this difference ($17,269) was IVIG-related total outpatient cost (intervention vs control groups: $64,080 vs $81,349, P=0.001).ConclusionThe patients in this high-touch IVIG clinical management program appeared to have comparable infections or adverse event rates and significantly lower total health costs compared to their matched controls.

show abstract

Tunel aorto-ventricular izquierdo: una rara entidad en cardiología pediátrica

Cited by 4 publications

References 0 publications

Outcome evaluation of a subcutaneous immunoglobulin clinical management program

Outcome evaluation of a subcutaneous immunoglobulin clinical management program

Espectro de las inmunodeficiencias primarias en un hospital de tercer nivel en un periodo de 10 años

Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy

Contact Info

Product

Resources

About

Tunel aorto-ventricular izquierdo: una rara entidad en cardiología pediátrica

Cited by 4 publications

References 0 publications

Outcome evaluation of a subcutaneous immunoglobulin clinical management program

Outcome evaluation of a subcutaneous immunoglobulin clinical management program

Espectro de las inmunodeficiencias primarias en un hospital de tercer nivel en un periodo de 10 años

Clinical and economic outcomes of a &quot;high-touch&quot; clinical management program for intravenous immunoglobulin therapy

Contact Info

Product

Resources

About

Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy